Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation

AIDS

Volumn 22, Issue 14, 2008, Pages 1719-1728

  Falutz, Julian ^a   Allas, Soraya ^b   Mamputu, Jean Claude ^b   Potvin, Diane ^b   Kotler, Donald ^c   Somero, Michael ^d   Berger, Daniel ^e   Brown, Stephen ^f   Richmond, Gary ^g   Fessel, Jeffrey ^h   Turner, Ralph ⁱ   Grinspoon, Steven ^j  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^c College of Physicians and Surgeons ^*  (United States)

^d DESERT REGIONAL MEDICAL CENTER   (United States)

^e AIDS Research Alliance   (United States)

^f AIDS Research Alliance   (United States)

^g Kaiser Foundation Research Institute ^*

^h KAISER PERMANENTE   (United States)

ⁱ Phase V Technologies Inc   (United States)

^j MASSACHUSETTS GENERAL HOSPITAL   (United States)

more..

Author keywords

Central fat accumulation; Growth hormone releasing factor; HIV lipodystrophy; Safety

Indexed keywords

ANTIRETROVIRUS AGENT; GROWTH HORMONE RELEASING FACTOR; PLACEBO; TESAMORELIN; UNCLASSIFIED DRUG;

ABDOMINAL FAT; ADULT; ANUS CANCER; ARTHRALGIA; ARTICLE; BACKACHE; BLEEDING; CELLULITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COUGHING; DIARRHEA; DIZZINESS; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION SITE ERYTHEMA; INJECTION SITE PRURITUS; INJECTION SITE URTICARIA; INTESTINE PERFORATION; LUDWIG ANGINA; MALE; NAUSEA; PAIN; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RHINOPHARYNGITIS; SINUSITIS; SPONTANEOUS ABORTION; TACHYCARDIA; UPPER RESPIRATORY TRACT INFECTION; WAIST HIP RATIO;

ADIPONECTIN; ANTI-RETROVIRAL AGENTS; BIOLOGICAL MARKERS; BODY COMPOSITION; C-REACTIVE PROTEIN; CHOLESTEROL; CROSS-OVER STUDIES; FEMALE; GROWTH HORMONE-RELEASING HORMONE; HIV-1; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INTRA-ABDOMINAL FAT; MALE; MIDDLE AGED; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 58149273826     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32830a5058     Document Type: Article

References (17)

1. Mallon PW, MillerJ, Cooper DA, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1 -infected men starting therapy. AIDS 2003; 17:971 -979.
2. DubeM, Parker RA, Tebas P, GrinspoonSK, Zackin RA, Robbins GK, et al. Glucose metabolism, lipid and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efa-virenz plus dual nucleosides. AIDS 2005; 19:1807-1818.
3. Grinspoon S, Carr A. Cardiovascular risk and body fat abnormalities in HIV-infected adults. N EnglJ Med 2005; 352:48-62.
4. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with HIV disease. J Clin Endocrinol Metab 2007; 92:2506-2512.
5. Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.
6. Ammassari A, Antinori A, Cozzi-Lepri A, Trotta MP, Nasti G, Ridolfo AL, et al. Relationship between HAART adherence and adipose tissue alterations. J Acquir Immune Defic Syndr 2002; 31 (Suppl 3):140-144.
7. Duran S, Saves M, Spire B, Cailleton V, Sobel A, Carrieri P, et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS 2001; 15:2441-2444.
8. Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, et al. Metabolic effects of a growth hormone releasing factor in patients with HIV. New Engl J Med 2007; 357:2359-2370.
9. Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sorensen HT, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007; 146:87-95.
10. ThornerM, Rochiccioli P, ColleM, Lanes R, GruntJ, Galazka A, et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. J Clin Endocrinol Metab 1996; 81:1189-1196.
11. ThornerMO, Rogol AD, Blizzard RM, Klingensmith GJ, NajjarJ, Misra R, et al. Acceleration of growth rate in growth hormone-deficient children treated with human growth hormone-releasing hormone. Pediatr Res 1988; 24:145-151.
12. Lievre M, Chatelain P, Van Vliet G, Olivier M, Blanchard J, Morre M, et al. Treatment with growth hormone-releasing hormone (GHRH) 1-44 in children with idiopathic growth hormone deficiency: a randomized double-blind dose-effect study. The GHRH European Multicenter Study (GEMS) Group. Fundam Clin Pharmacol 1992; 6:359-366.
13. Chen RG, Shen YN, Yei J, Wang CF, Xie DH, Wang XH, et al. A comparative study of growth hormone (GH) and GH-releasing hormone (1-29)-NH2 for stimulation of growth in children with GH deficiency. Acta Paediatr Suppl 1993; 388:32-35.
14. Kotler DP, Muurahainen N, Grunfeld C, Wanke C, Thompson M, Saag M, et al. Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. J Acquir Immune DefSyndr 2004; 35:239-252.
15. Grunfeld C, Thompson M, Brown SJ, Richmond G, Lee D, Muurahainen N, et al. Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12 week induction and 24-week maintenance therapy. J Acquir Immune Defic Syndr 2007; 45:286-297.
16. Biller BM, Sesmilo G, Baum HB, Hayden D, Schoenfeld D, Klibanski A. Withdrawal of long-term growth-hormone (GH) administration: differential effects on bone density and body composition in men with adult-onset GH deficiency. J Clin Endocrinol Metab 2000; 85:970-976.
17. Lo J, You S, Canavan B, Liebau J, Beltrani G, Koutkia P, et al. Effects of 18-month physiological GH replacement in relatively GH-deficient patients with HIV lipodystrophy. In: 15th Conference on Retroviruses and Opportunistic Infections; Boston, MA; 2008.